NCT06758544 A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
| NCT ID | NCT06758544 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Guangdong Provincial People's Hospital |
| Condition | Pancreatic Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 18 participants |
| Start Date | 2025-03-17 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 18 participants in total. It began in 2025-03-17 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of resectable pancreatic cancer.
Eligibility Criteria
Inclusion Criteria: 1. Subject voluntarily agrees to participate in this study and signs an Institutional Review Board -approved informed consent prior to performing any of the Screening Visit procedures. 2. Males and females at 18-75 years of age, inclusive, at the Screening Visit. 3. Have a clinical diagnosis of pancreatic cancer. 4. An Eastern Cooperative Oncology Group (ECOG) score of 0 or 1. 5. Expected survival time of≥6 months. 6. No serious hematologic and cardiac abnormalities of the liver, kidneys, or coagulation functions. Exclusion Criteria: 1. Prior treatment with other oncolytic virus or systemic therapy for pancreatic cancer. 2. Previous allogeneic hematopoietic stem cell transplantation or organ transplantation. 3. Immunocompromised patients. 4. Known alcohol or drug dependency. 5. Women who are pregnant or breastfeeding.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06758544 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06758544 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06758544 currently recruiting?
Yes, NCT06758544 is actively recruiting participants. Contact the research team at chenrf63@163.com for enrollment information.
Where is the NCT06758544 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06758544 clinical trial?
NCT06758544 is sponsored by Guangdong Provincial People's Hospital. The trial plans to enroll 18 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.